Showing results (1-10 of 83) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2018
The Impact of Early-Phase Trial Design in the Drug Development ProcessMark R Conaway, Gina R PetroniBMC Cancer|February 7, 2018
A web tool for designing and conducting phase I trials using the continual reassessment methodNolan A Wages, Gina R PetroniContemporary Clinical Trials|February 2, 2015
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanomaNolan A Wages, Craig L Slingluff, Gina R PetroniPharmaceutical Statistics|May 13, 2015
A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trialNolan A Wages, Paul W Read, Gina R PetroniEuropean Urology|April 23, 2003
The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapyTracey Krupski, Eric A Bissonette, Gina R Petroni, et al.Statistics in Medicine|March 2, 2016
Implementation of adaptive methods in early-phase clinical trialsGina R Petroni, Nolan A Wages, Gautier Paux, et al.Head & Neck|June 2, 2021
Phase II randomized study of preoperative calcitriol to prevent hypocalcemia following thyroidectomyDavid C Shonka, Anne K Maxwell, Gina R Petroni, et al.Cancer Immunology, Immunotherapy : CII|December 7, 2019
Tailoring early-phase clinical trial design to address multiple research objectivesNolan A Wages, Craig L Slingluff, Timothy N Bullock, et al.Contemporary Clinical Trials|July 28, 2021
Operating characteristics are needed to properly evaluate the scientific validity of phase I protocolsNolan A Wages, Bethany Jablonski Horton, Mark R Conaway, et al.Cancers|March 28, 2025
Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity AttributionNolan A Wages, Bethany J Horton, Li Liu, et al.Pageof 9